GNLX GENELUX Corp
Price Chart
Executive Summary
Two Genelux insiders (a Director and the Head of Regulatory) sold a total of $30K in open-market sales over a 7-day window. While the insider count is modest, the $30K aggregate amounts to only ~0.02% of the $135M market cap—well below the 0.1% materiality threshold—making these routine, non-informative sales. The company has high analyst bullishness (92% buy/strong buy), and past insider activity has been exclusively selling ($43K in the prior 30 days), suggesting ongoing diversification/vesting patterns rather than informed bearish signaling.
Key Financial Metrics
Actionable Insight
These sales are too small to read as a bearish signal—alert only if a material insider ($1M+) opens a sale cluster or if a C-suite officer sells >$500K. GNLX's strong analyst consensus and past neutral calls that outperformed suggest the market remains bullish on fundamentals. Monitor any insider open-market BUY as a stronger signal.
Key Facts
- Two insiders sold a combined 10,192 shares in open-market transactions totaling ~$30K.
- Sales represent only 0.02% of GNLX's $135M market cap—trivial by proportionality standards.
- Director Thomas John sold 10,000 shares (~$30K); Head of Regulatory Smalling Ralph sold 192 shares (~$563).
- No 10b5-1 plan flag noted, but the pattern is consistent with routine portfolio rebalancing given the small dollar amounts and recurring insider sales over the past 30 days.
- 92% of analysts rate the stock Buy or Strong Buy; the stock trades near recent highs at $2.93.
Financial Impact
~$30K in aggregate insider sales, which is 0.02% of market cap—immaterial.
Risk Factors
- If a larger insider (CEO/CFO) begins selling material amounts, it could signal management discomfort with valuation.
- Small pharma stocks are volatile—any regulatory or pipeline setback could amplify downside beyond what insider activity suggests.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-GNLX-1780619736520 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
8d ago
|
Insider Cluster
| $3.06 awaiting T+5 | awaiting T+5 | — | $2.96 (−3.27%) |
|
May 11, 2026
4w ago
|
Insider Cluster
| $2.90 $2.85 | ▼ −1.72% | ▼ −1.64% | $2.96 (+2.07%) |
|
Apr 29, 2026
6w ago
|
DEFA14A
| $2.50 $2.77 | ▲ +10.80% | ▲ +7.69% | $2.96 (+18.40%) |
|
Mar 24, 2026
11w ago
|
Insider Cluster
| $2.42 $2.42 | · 0.00% | ▲ +0.42% | $2.96 (+22.31%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $2.40 $2.48 | ▲ +3.33% | ▲ +5.48% | $2.96 (+23.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access